NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

MEDICAL TECHNOLOGIES EVALUATION PROGRAMME

Equality impact assessment – Guidance development

The XprESS Multi-Sinus Dilation System for the treatment of chronic rhinosinusitis

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

Consultation

 Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

No equality issues were identified during scoping

2. Have any other potential equality issues been highlighted in the company's submission, or patient organisation questionnaires, and, if so, how has the Committee addressed these?

No equality issues were identified in the company's submissions or by patient organisations

3. Have any other potential equality issues been identified by the Committee and, if so, how has the Committee addressed these?

No equality issues were identified by the Committee

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared

| | with other groups? If so, what are the barriers to or difficulties with access for the specific group? |
|-----|--|
| No | |
| | |
| 5. | Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
| No | |
| | |
| 6. | Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to , or difficulties with access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality? |
| N/A | |
| | |
| 7. | Have the Committee's considerations of equality issues been described in the medical technology consultation document, and, if so, where? |

Approved by Associate Director (name): Mark Campbell

N/A – There were no equality issues that required consideration

Date: 15 June 2016

Medical technologies guidance document

| 1. | Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these? |
|-----|---|
| No | |
| | |
| 2. | If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group? |
| N/A | |
| | |
| 3. | If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
| N/A | |
| | |
| 4. | If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality? |
| N/A | |
| | |
| 5. | Have the Committee's considerations of equality issues been described in the medical technologies guidance document, and, if so, where? |
| | |

N/A – There were no equality issues that required consideration

Approved by Centre or Programme Director (name): Mirella Marlow

Date: 7 December 2016